Literature DB >> 28438621

HER2 loss after neoadjuvant treatment: is the adjuvant trastuzumab treatment feasible?

Kadri Altundag1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28438621     DOI： 10.1016/j.humpath.2017.02.025

Source DB:  PubMed          Journal:  Hum Pathol        ISSN： 0046-8177            Impact factor:   3.466


× No keyword cloud information.
  1 in total

1.  Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations.

Authors:  Hidejiro Torigoe; Kazuhiko Shien; Tatsuaki Takeda; Takahiro Yoshioka; Kei Namba; Hiroki Sato; Ken Suzawa; Hiromasa Yamamoto; Junichi Soh; Masakiyo Sakaguchi; Shuta Tomida; Kazunori Tsukuda; Shinichiro Miyoshi; Shinichi Toyooka
Journal:  Cancer Sci       Date:  2018-04-15       Impact factor: 6.716
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.